Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06807840 · ClinicalTrials.gov registry record

Flu Infection at UPHS

A clinical trial of Influenza, Human, sponsored by University of Pennsylvania.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT06807840: Recruiting study of Influenza, Human, sponsored by University of Pennsylvania.

NCT06807840 is a study of Influenza, Human that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 50 participants, below the 16,221-participant average among 18 other Influenza, Human trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06807840, a study of Influenza, Human, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

Cellular and humoral immune responses in individuals with active influenza infection will be assessed. Each year, up to 50 participants will be enrolled. The investigators hypothesize that influenza infection will elicit mostly memory immune responses rather than de novo immune responses to infection.

Primary Outcome

The investigators will compare neutralizing antibodies in sera, plasma, and nasal swab samples against the influenza strain that each participant is infected with as well as historical and recently circulating influenza virus strains. Antibody titers between different strains will be compared to understand if memory or de novo immune responses are generated following influenza infection based on inferred influenza exposure history.

Conditions Studied

Interventions

  • OTHER influenza virus infection

Study Locations (1)

Pennsylvania

  • Penn Presbyterian Medical Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-01-27
Est. Completion 2026-09-30
University of Pennsylvania

1,423 total trials

What NCT06807840 shows while recruiting

NCT06807840 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 16,221-participant average among 18 other Influenza, Human trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 1 intervention - of which influenza virus infection is the first listed.

NCT06807840 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06807840 about?

NCT06807840 is a clinical study titled "Flu Infection at UPHS". Cellular and humoral immune responses in individuals with active influenza infection will be assessed. Each year, up to 50 participants will be enrolled. The investigators hypothesize that influenza infection will elicit mostly memory immune responses rather than de novo immune responses to infectio...

What is the current status of trial NCT06807840?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-01-27. Estimated completion is 2026-09-30.

What conditions does trial NCT06807840 study?

This clinical trial studies the following conditions: Influenza, Human.

What interventions are being tested in trial NCT06807840?

The interventions under investigation include: influenza virus infection (OTHER).

Who is sponsoring clinical trial NCT06807840?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06807840 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Influenza, Human

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06807840's enrollment target sits among peer trials

50 15th of 18 higher than 4 of 18 other Influenza, Human trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Influenza, Human trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06807840, the US trial registry maintained by the National Library of Medicine. NCT06807840 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.